| Protocol Number | Protocol Class | Protocol Title | Current Phase | Slots Available | Slots on Hold | Status |
| 2115 | B | ATO + RT (once a week) | I | 0 | 0 | CLOSED |
| 2115 | B | ATO + RT (twice a week) | I | 0 | 0 | CLOSED |
| 0306 | B | EMD | II | 0 | 0 | CLOSED |
| 0501 | B | POLY-ICLC | II | 0 | 0 | CLOSED |
| 0602 | B | AT-101 (ARM 1) | I | 0 | 0 | CLOSED |
| 0602 | B | AT-101 (ARM 2) | I | 0 | 0 | CLOSED |
| 0603 | B | HCQ | I | 0 | 0 | TEMP CLOSED |
| 0703 | B | BSI (Group 1: 4 weeks) | I | 4 | 1 | OPEN |
| 0703 | B | BSI (Group 2: 10 weeks) | I | 5 | 0 | OPEN |
| 0502 | C | BAY/OSI | II | 0 | 0 | CLOSED |
| 0504 | C | MLN518 | feasibility | 0 | 0 | CLOSED |
| 0504 | C | MLN518 | I | 0 | 0 | TEMP CLOSED |
| 0503 | C | EM-1421 (P450) | I | 2 | 1 | OPEN |
| 0503 | C | EM1421 (Non P450) | I | 0 | 3 | TEMP CLOSED |
| 0702 | C | AT-101 PHASE II | II | 0 | 2 | TEMP CLOSED |
| 2201 | E | RITUXIMAB | II | 4 | 0 | OPEN |
| 0107 | F | GLIOMA GENE EXPRESSION | N/A | NO LIMIT | 0 | OPEN (if amend. 10/25/05 approved) |
| 0305 | F | CD4 Count (High Grade) | N/A | 1 | 0 | OPEN |
| 0305 | F | CD4 Count (Low Grade) | N/A | 22 | 0 | OPEN |
| 0307 | F | BLOOD CLOT | N/A | 0 | 0 | CLOSED |
| 0402 | F | PLASMA BIOMARKERS | N/A | 0 | 0 | CLOSED |